Fampridine effect on Parkinson disease symptoms

Evaluation of the effects of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson: A randomized double blind trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230905059361N1

Enrollment

Registered

2023-10-03

Start date

2023-09-22

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: One group will receive fampridine tablets (Cinagen Pharmaceutical Company) as the intervention group. The new drug will be part of their treatment regimen along wit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Known Parkinson's disease presence of Parkinson's symptoms in the patient The symptoms are not due to other diseases (such as stroke, trauma, etc.) No interaction with other drugs No history of seizures

Exclusion criteria

Exclusion criteria: Reluctance to cooperate Interference of the intervention drug with usual drugs Aggravation of the patient's symptoms History or occurrence of seizures

Design outcomes

Primary

Measure	Time frame
Motor and non-motor symptoms of Parkinson's disease. Timepoint: Before and after the start of the intervention. Method of measurement: Using the MDS-UPDRS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Shams

Shahre-kord University of Medical Sciences

Mohammadsh3428@gmail.com+98 38 3333 9940

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026